【T-705 (Favipiravir)】齊一生科技（上海）有限公司感謝您的查閱與咨詢！期待與您的真誠合作!

低價(jià)格現(xiàn)貨供應(yīng),歡迎前來選購齊一生物銷售：021－6034 8496；181214 53965；173021 04490網(wǎng)站：www.qiyibio.com【T-705 (Favipiravir)】

133276    NeXtalStock Spermine (100)        CNY                           

4503065  artus CMV LC PCR Kit (96) CE           CNY                           

6000-5000      Specimen Collection Tubes           CNY                            【T-705 (Favipiravir)】

5000-1430      MST Vortexer II - FoamFeetAssembly, 110V              CNY                           

5128-1220      Specimen Transport Medium (STM) CE             CNY                           

5123-1220      Female Swab Specimen Collection KitTM           CNY                           

5100-1400IVD       hc2 Sample Conversion Kit           CNY                           

EA11424 EASYartus BKV RG_II         CNY                           

5050-1075 V.1       CD Rom Manual, MST Vortexer 2        CNY                           

EA10124 EASYartus EBV RG PCR Kit 2             CNY                           

BR-02     DxS B-RAF Mutation Test Kit              CNY                           

9240729  Tubing, 3/8"OD , Red, AP            CNY                           

9240719  Cable Carrier, Capper, Elevator, AP              CNY                           

9240701  O-Ring, Shaker, Lower Body, AP96/196             CNY                           

9240696  Fitting, Barbed, 1/4" ID tube, AP          CNY                           

9243651  Comprehen Valid., QIAgility   """The Comprehensive Validation Support plan specific to a laboratory＇s needs will incorporate all of the requirements for the internal validation guidelines from the FBI＇s Quality Assurance Standards (QAS).

The Comprehensive Validation Support service includes all travel ａnd labor charges for up to 20 days by the QIAGEN Validation Team. Typically, one week will be required to extract, quantify, ａnd amplify the validation study samples ａnd may require multiple individuals. Usually, two weeks is required to analyze the data ａnd one week to write the final report. The expected time period to complete the Comprehensive Validation is six weeks. The actual time may vary depending on resource availability, including laboratory time dedicated to validation activities.

Lab Work – The QIAGEN specialist(s) will travel to the laboratory to conduct the on-site validation lab work. The QIAGEN specialist team will perform ａnd complete all extractions, quantifications, amplfications, ａnd capillary electrophoresis. The laboratory is responsible for providing systems/protocols that may be needed (generally laboratory SOPs, ex. interpretation guidelines). Additionally, the laboratory staff may be required to provide additional data needed for interpretation (ex. quantification/amplification/CE results) during the data review phase of the validation.

Once the final scope of the validation is determined, QIAGEN will provide a quote for all consumables required for the validation.  Non-QIAGEN chemistry ａnd accessories are not included ａnd should  be purchased to cover the validation experimental design including qPCR, STR, NIST standards, required samples types (blood, semen, buccal samples) ａnd required substrates (swabs, materials, etc).   For planning purposes ａnd to ensure a smooth process, the Customer is expected to have all materials on-hand ａnd inventoried one (1) week prior to the validation start date.

Data Analysis – The Comprehensive Validation Support plan encompasses data collection (quants, amps, CE) during the on-site visit. The laboratory may be responsible for sharing (typically electronically via e-mail) any validation data requested after the on-site visit. A QIAGEN specialist will complete all of the data analysis produced from the validation study design. This includes qPCR (quant) ａnd STR (amp) analysis ａnd linkage to starting samples.

Validation data CD/flashdrive – QIAGEN will review the validation data ａnd draft a validation summary document, ensuring compliance with the FBI＇s QAS requirements/standards. QIAGEN will send validation data in an electronic format (email/CD/flashdrive) to the laboratory. The laboratory is responsible for final compilation, any format change preferences, review ａnd signoff of the validation report. The documentation provided by QIAGEN will aide in demonstrating compliance with all accreditation guidelines during laboratory audits. Should a hard copy of the validation study be preferred, the laboratory is required to specify prior to the onset of the validation.

Post-validation QIAGEN-to-Laboratory Transfer – Following completion of the validation ａnd generation of the draft validation summary document, a designated member of the QIAGEN validation team will review the validation with the Lab Manager ａnd the Technical Leader. Following sign off on the validation report, training of the laboratory DNA staff will occur. Refer to the Post-validation Competency Training for additional information. """   CNY                           

218076    miScript SYBR Green PCR Kit (2000)         CNY                           

271906    cattletype Milk Prep Kit (50)         CNY                           

289980    intype IC-DNA (1ml)            CNY                            【T-705 (Favipiravir)】

280437    virotype BTV RT-PCR Kit (480)           CNY                           

932836    #QIAsymphony Ni-NTA Denat. Kit (384)            CNY                           

800511    Verification Sequencing / DNA production           CNY                           

9238243  ZLV BioRobot M96 User Manual          CNY                           

9019988  ZLV Mainboard, QGY           CNY                           

9020553  Foam angle, transport box, QIAC         CNY                           

9020582  X-Motor, DML3000             CNY                           

9020584  Y-Belt, DML3000 320 Teeth         CNY                           

9020594  Enclosure, DML3000            CNY                           

9021006  Motor, Pipettor Y, DCU         CNY                           

9236333  Sample Loop          CNY                           

QY-x2012       SF767 腦瘤 瘤株                                   

QY-x2013       MLA-144 長臂猿淋巴瘤 1640+10%胎牛血清                                    

QY-x2014       T47D 乳腺導(dǎo)管癌 1640+15%胎牛血清                                      

QY-x2015       ZR-75-1 乳腺導(dǎo)管癌 1640+10%胎牛血清                                   

QY-x2016       A875 黑色素瘤 1640+10%胎牛血清                                    

QY-x2017       SK-HEL-1 皮膚黑色素瘤                                       

QY-x2018       A431 皮膚基底細(xì)胞癌                                    【T-705 (Favipiravir)】

QY-x2019       Jurkat 急性T淋巴細(xì)胞白血病 1640+10%胎牛血清                                         

QY-x2020       U937 單核細(xì)胞白血病 1640+10%胎牛血清                                       

QY-x2021       MJ 淋巴瘤 1640+10%胎牛血清                                   

QY-x2022       CEM 白血病 1640+10%胎牛血清                                       

QY-x2023       K562 慢性髓原白血病 1640+10%胎牛血清                                       

QY-x2024       HPB-ALL T細(xì)胞白血病 1640+10%胎牛血清                                      

QY-x2025       HL-60 白血病 1640+10%胎牛血清                                      

QY-x2026       Daudi B淋巴細(xì)胞瘤 1640+10%胎牛血清                                    

QY-x2027       SK-BR-3 乳腺腺癌 1640+15%胎牛血清                                     

QY-x2028       MCF-7 乳腺腺癌 1640+10%胎牛血清                                        

QY-x2029       MCF-7/Adr 乳腺腺癌/阿霉素耐藥株 1640+10%胎牛血清                                        

QY-x2030       A2780 卵巢癌 1640+10%胎牛血清                                     

QY-x2031       CoC1 卵巢癌 1640+10%胎牛血清                                       

QY-x2032       CoC2 卵巢癌 1640+10%胎牛血清                                       

QY-x2033       OVCAR-3 卵巢癌 DMEM+10%胎牛血清                                    

QY-x2034       SK-OV-3 卵巢腺癌 1640+10%胎牛血清                                      【T-705 (Favipiravir)】

QY-x2035       SK-OV-3/DDP 卵巢腺癌順鉑耐藥株 1640+10%胎牛血清                                        

QY-x2036       HeLa 宮頸癌 1640+10%胎牛血清                                       

QY-x2037       HeLaS3 宮頸癌 1640+10%胎牛血清                                    

QY-x2038       HEC-1B 子宮內(nèi)膜癌                                      

QY-x2039       JEG-3 絨癌 1640+10%胎牛血清                                         

QY-x2040       Du145 前列腺癌 高糖DMEM+10%胎牛血清                                    

QY-x2041       LNCaP 前列腺癌                                    

QY-x2042       LNCaP clone 前列腺癌                                   

QY-x2043       PC-3 前列腺癌 DMEM+10%胎牛血清